SCHEMBL25814053

SCHEMBL25814053

CCc1c(C)[nH]c2ccc(C(=O)N(C)CCN3CCC3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 11/20 0.46
TLR7 Q9NYK1 11/20 0.46
TLR8 Q9NR97 10/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
GFER P55789 1/20 0.41
PSMD14 O00487 1/20 0.39
RECQL P46063 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25811995 0.97 KMT2A (0.49) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25815082 0.93 TLR9 (0.46) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25811810 0.91 TLR9 (0.48) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25811987 0.88 KMT2A (0.58) KDM4EALDH1A1HSD17B10HPGDALOX15
SCHEMBL25811801 0.86 KMT2A (0.61) KDM4EALDH1A1HSD17B10HPGDALOX15
SCHEMBL25815032 0.85 KMT2A (0.45) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25812014 0.82 KMT2A (0.49) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25813335 0.81 TLR8 (0.53) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25811273 0.80 KMT2A (0.64) TLR9TLR7TLR8KDM4EALDH1A1
SCHEMBL25814483 0.79 ALDH1A1 (0.53) KDM4EALDH1A1HPGDKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 TLR9 4628/4885TLR7 4556/4885TLR8 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.